On 30 May, Jon Pilcher said that he was hopeful that the outcome of ROW would come soon and that he hadn’t and wouldn’t commence any discussions re 2591 partnering until the first Phase 2 results were in.
I think it’s fair to assume that discussions re partnering will commence very soon after December results are in….although I’m sure plenty of preliminary work has been done already
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-28
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |